|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
This excerpt taken from the ABII 8-K filed Apr 1, 2008. Upcoming Scientific Congresses Clinical data from various studies of ABRAXANE and additional pipeline compounds will be reported at three upcoming international congresses: American Academy of Clinical Research (AACR) in April 2008 where 11 submissions have been accepted; European Breast Cancer Conference (EBCC) in April 2008 where 13 submissions have been accepted; and American Society of Clinical Oncology (ASCO) in May 2008 where 23 submissions have been accepted. The studies to be presented include the use of ABRAXANE as mono-therapy and in combination therapy in breast cancer and other tumor types, including melanoma, pancreatic, prostate and ovarian. |
| |||||||